Innoviva PE Ratio 2010-2024 | INVA
Current and historical p/e ratio for Innoviva (INVA) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Innoviva PE ratio as of January 31, 2025 is 9.84.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Innoviva PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2025-01-31 |
18.64 |
|
15.40 |
| 2024-09-30 |
19.31 |
$1.21 |
15.96 |
| 2024-06-30 |
16.40 |
$1.21 |
13.55 |
| 2023-12-31 |
16.04 |
$2.18 |
7.36 |
| 2023-09-30 |
12.99 |
$0.44 |
29.52 |
| 2023-06-30 |
12.73 |
$-0.08 |
0.00 |
| 2023-03-31 |
11.25 |
$2.70 |
4.17 |
| 2022-12-31 |
13.25 |
$2.33 |
5.69 |
| 2024-03-31 |
15.24 |
$3.51 |
4.34 |
| 2022-09-30 |
11.61 |
$3.19 |
3.64 |
| 2022-06-30 |
14.76 |
$1.29 |
11.44 |
| 2022-03-31 |
19.35 |
$2.14 |
9.04 |
| 2021-12-31 |
17.25 |
$2.78 |
6.21 |
| 2021-09-30 |
16.71 |
$3.12 |
5.36 |
| 2021-06-30 |
13.41 |
$2.48 |
5.41 |
| 2021-03-31 |
11.95 |
$2.27 |
5.26 |
| 2020-12-31 |
12.39 |
$2.02 |
6.13 |
| 2020-09-30 |
10.45 |
$1.96 |
5.33 |
| 2020-06-30 |
13.98 |
$2.06 |
6.79 |
| 2020-03-31 |
11.76 |
$1.71 |
6.88 |
| 2019-12-31 |
14.16 |
$1.43 |
9.90 |
| 2019-09-30 |
10.54 |
$3.35 |
3.15 |
| 2019-06-30 |
14.56 |
$3.42 |
4.26 |
| 2019-03-31 |
14.03 |
$3.56 |
3.94 |
| 2018-12-31 |
17.45 |
$3.52 |
4.96 |
| 2018-09-30 |
15.24 |
$1.63 |
9.35 |
| 2018-06-30 |
13.80 |
$1.41 |
9.79 |
| 2018-03-31 |
16.67 |
$1.23 |
13.55 |
| 2017-12-31 |
14.19 |
$1.11 |
12.78 |
| 2017-09-30 |
14.12 |
$0.87 |
16.23 |
| 2017-06-30 |
12.80 |
$0.78 |
16.41 |
| 2017-03-31 |
13.83 |
$0.60 |
23.05 |
| 2016-12-31 |
10.70 |
$0.49 |
21.84 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.183B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
